Search Results for “EC” – Page 296 – media

Moderate kimchi intake linked to lower obesity rates, study shows

In a recent study published in the journal BMJ Open, researchers explored the relationship between kimchi consumption and obesity in South Korea. Obesity is associated with nutritional, environmental, and lifestyle factors and is a significant risk factor for diabetes, chronic kidney disease, cardiovascular disease, and hyperlipidemia. Obesity prevalence in South Korea has increased steadily over the years. Meanwhile, the prevalence of abdominal obesity has also increased over time. Increased obesity prevalence is associated with higher medical expenditure; thus, obesity prevention remains a public health priority. In Korea, kimchi is a traditional side dish low in calories but rich in vitamins, dietary fiber, polyphenols, and lactic acid bacteria. There are concerns about kimchi as one of the major contributors to sodium intake. A 2019-20 survey revealed that daily sodium intake from kimchi was 500 mg (15% of total sodium intake). Studies have shown associations between increased sodium intake and a greater ...
- Source: drugdu
- 84
- February 6, 2024
FDA clears painful diabetic neuropathy neurostim therapy from Neuralace

Neuralace Medical announced today that it received FDA clearance for its chronic painful diabetic neuropathy (PDN) treatment. San Diego–based Neuralace says this marks the first-ever FDA clearance of a non-invasive, magnetic peripheral nerve stimulation (mPNS) treatment for PDN. The company says its Axon Therapy could offer “new hope” to millions with the condition. Axon Therapy uses mPNS to deliver a quick, painless and non-invasive treatment in sessions lasting just 13.5 minutes, according to Neuralace. Each session utilizes magnetic pulses to provide relief for a potential improvement in pain management. Neuralace said a recent trial of 71 patients demonstrated efficiency, plus significant improvements in subject outcomes. The company believes its therapy represents a paradigm shift in PDN treatment. Axon Therapy offers a non-pharmacological and non-invasive option that could reduce dependence on medications and their associated side effects. The company says FDA clearance paves the way for broader access to innovative pain ...
- Source: drugdu
- 78
- February 6, 2024
FDA clears stereotactic guidance system from ClearPoint Neuro

ClearPoint Neuro (Nasdaq:CLPT) announced today that it received FDA 510(k) clearance for its SmartFrame OR stereotactic system. Solana Beach, California–based ClearPoint Neuro developed its SmartFrame OR system with two main components. It features the SmartFrame OR technology with the ClearPointer optical navigation wand. SmartFrame OR offers stereotactic guidance for placing and operating instruments or devices in neurological procedures. It helps during the planning and operation processes of these procedures, performed in conjunction with using a compatible optical stereotaxic navigation system using preoperative MR and/or CT imaging. These procedures include biopsies, catheter placements and electrode introduction. ClearPoint Neuro’s ClearPointer works with SmartFrame OR and a compatible stereotactic optical navigation system. It helps with patient registration and navigation. SmartFrame OR can be used with or without available bone screw fiducials. ClearPoint Neuro plans to begin a limited market release of the system in the first half of 2024. It earmarked the second ...
- Source: drugdu
- 79
- February 6, 2024
Hengrui ADC Innovative Drug SHR-A1811 HER2 Positive Gastric Cancer Indication Proposed to be Included in Breakthrough Therapy Variety

This study was led by Professor Jin Li of Dongfang Hospital, Tongji University, with the participation of a total of 17 centers across China. Previously, four other indications of SHR-A1811 have been included in the list of breakthrough therapeutic varieties by the Drug Evaluation Center of the State Drug Administration, and the indications are: recurrent or metastatic breast cancer with low expression of HER2, HER2-positive recurrent or metastatic breast cancer, HER2-mutated advanced non-small-cell lung cancer that has failed previous platinum-containing chemotherapy, and advanced non-small-cell lung cancer that has failed previous treatments of oxaliplatin, fluorouracil, and irinotecan, and has failed previous treatments of oxaliplatin, fluorouracil, and irinotecan. irinotecan treatment failure, and HER2-positive colorectal cancer. In 2020, gastric cancer ranks 5th in global cancer incidence and 4th in mortality. HER2-positive gastric cancer is a unique disease subtype that requires different treatment strategies from HER2-negative gastric cancer. The global HER2-positive rate of gastric ...
- Source: drugdu
- 110
- February 6, 2024
Barbra Streisand’s nonprofit runs PSA to educate women about heart attack symptoms

Barbra Streisand’s Women’s Heart Alliance wants people to know when to ask, “what’s up, doc?” In a new PSA campaign, the nonprofit is trying to educate women about the gender-specific symptoms of heart attacks to stop them dying at a higher rate than men. The PSA moves quickly to catch the viewer’s attention, opening with the line: “Listen up, women and everyone who loves a woman, heart disease kills one of us every 80 seconds, and we die of heart attacks at twice the rate of men.” Those statistics are displayed in unmissable, screen filling text as the voice-over reads them out. In the next section, the voice-over explains a reason for the discrepancy in health outcomes, stating that “when a woman is having a heart attack, our symptoms are too often missed, or dismissed, even by doctors.” The situation is “a serious crisis.” The alliance sees education as the ...
- Source: drugdu
- 78
- February 6, 2024
As Humira plummets, AbbVie dials up Rinvoq and Skyrizi estimates to a combined $27B

As AbbVie slogs through sharp revenue declines for Humira, the company is looking to the immunology light at the end of the tunnel. During the final quarter of 2023, sales of Humira—which once sat pretty as the world’s best-selling drug—plunged nearly 41% to $3.3 billion globally. The rate of erosion seems to have gathered steam in the fourth quarter and outpaced the med’s full-year sales decline of around 32%. Still, AbbVie and investors knew this blow was coming. The plan—following the entry of Humira biosimilars early last year—is to weather the brunt of the attack in 2024 before charting a return to growth in 2025 and beyond, Robert Michael, AbbVie’s chief operating officer, said on a call with investors Friday. Specifically, AbbVie will rely on its roster of growth products, including Humira’s immunology heirs Rinvoq and Skyrizi, to help “absorb the largest loss of exclusivity event to date across our ...
- Source: drugdu
- 78
- February 6, 2024
BMS runs first branded TV spot for Camzyos, focusing on moments its $13B heart disease drug makes

Bristol Myers Squibb is stepping up promotion of its $13.1 billion heart disease drug Camzyos, launching the first branded TV spot as it seeks to penetrate the market ahead of the anticipated arrival of a rival. The 90-second commercial focuses on Mike, a person living with symptomatic obstructive hypertrophic cardiomyopathy (HCM), as he hikes through an idyllic landscape. As Mike says in the voice-over, “there were some days I was so short of breath I thought I’d have to settle for never stepping foot on this trail again.” Now, Mike takes Camzyos, and his symptoms have improved. After talking through his experience with HCM, Mike delivers a closing piece to the camera, telling the audience that “this is my Camzyos moment.” BMS decided on “My Camzyos Moment” as the focus of its direct-to-consumer campaign after talking to patients. “We have consistently heard from patients about moments that seemed little, but ...
- Source: drugdu
- 72
- February 6, 2024
FDA Issues Warning of Contaminated Copycat Eyedrops

Mike Hollan The agency issued the warning against three brands of unapproved eyedrops designed to look like an approved brand. Be careful what you put in your eye. FDA has issued a warning for consumers to be on the lookout for copycat eyedrops.1 Specifically, consumers should be wary of purchasing eye drops that are designed to look like Bausch + Lomb’s Lumify brand. While Lumify is approved for redness relief, the noted brands are not approved by FDA. The brands are as follows: South Moon, Rebright, and FivFivGo. The agency’s warning was posted with an image showing how the three brands packaging and branding is designed to look exactly like Lumify. While each brand is clearly marked with its own name, the box’s all use the same color scheme and each feature the same drawing of a women’s eye with a purple tint to it. The drug information is also ...
- Source: drugdu
- 121
- February 5, 2024
CSPC Pharmaceutical Group’s SYS6002’s first human study unveiled at ASCO-GU

From January 25th to 27th local time, the 2024 American Society of Clinical Oncology Urogenital Oncology Branch (ASCO-GU) annual meeting was grandly held in San Francisco. ASCO GU is an academic event in the field of urogenital tumors. The conference will showcase the most innovative scientific progress in this field and discuss the future treatment directions of urogenital tumors. The first human study of SYS6002, a collaboration between CSPC and Fudan University Cancer Hospital’s Professor Ye Dingwei’s team and Professor Zhang Jian’s team – “Evaluating the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SYS6002 in patients with advanced solid tumors “An open, single-arm, multi-center phase I clinical trial” – phased research results were presented at the conference in the form of a poster (number B622). Research methods This study is a single-arm, open, multi-center phase I study. Aims to evaluate the safety, tolerability and PK characteristics of SYS6002 in ...
- Source: drugdu
- 133
- February 5, 2024
NHS launches BRCA testing programme for people of Jewish descent

Individuals with Jewish ancestry are six times more likely to carry a genetic fault.The NHS has announced the launch of a new BRCA gene testing programme to identify cancer risk early in individuals with Jewish ancestry. People with Jewish ancestry are about six times more likely to carry a genetic fault, which can increase the risk of developing some cancers, than the general population. Across the next two years, the national NHS Jewish BRCA Testing Programme plans to identify thousands more people carrying faults in the BRCA genes so they can seek early access to surveillance and prevention services. In alignment with the health services drive to catch tumours earlier, when they are easier to treat, anyone over the age of 18 years with Jewish ancestry will be eligible to receive a simple genetic saliva test to look for the presence of BRCA1 or BRCA2 faults. BRCA1 and BRCA2 are ...
- Source: drugdu
- 125
- February 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.